Bull case
Ovid Therapeutics is viewed favorably because its lead asset OV329 is a redesigned, next-generation GABA-AT inhibitor that preserves vigabatrin’s validated anti-seizure mechanism while aiming to eliminate the retinal toxicity and gram-scale dosing that limited the older drug, with Phase 1 showing clean tolerability across 68 volunteers and no ophthalmologic findings. The company also has meaningful commercial upside in ultra-orphan epilepsy markets such as TSC, infantile spasms, and refractory focal onset seizures, where management and analysts cite peak revenue potential exceeding $600M and, for TSC/IS combined, more than $700M given differentiated pediatric pricing. Near-term value is further supported by multiple catalysts, including an OV329 photosensitivity readout expected near YE/early 2027, a dose-confirmatory focal seizure study slated for completion in 2H27, and cash runway into 2029, all of which reduce execution risk and keep optionality from OV4071 and soticlestat in play.